Live
BioPharma DiveBristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlookFierceBiotechCBER chief Prasad steps aside, deputy takes the reins as search for successor continuesFierceBiotechJ&J axes $5B CAR-T dream months after touting best-in-disease efficacyEndpoints NewsSummit slips on ivonescimab's apparent interim miss in sign of investor frustrationEndpoints NewsAmgen files update to Tavneos label as FDA escalates push to withdrawFierceBiotechChutes & Ladders—Astellas appoints new top strategist from Sanofi JapanFierceBiotechLigand tries to disembark from part of Viking pact, alleging contract breachCellBringing the genetically minimal cell to life on a computer in 4DIlluminaCanaccord cuts Illumina stock price target on competition concerns - Investing.comEndpoints NewsSeaport, Hemab price IPOs, while Avalyn soars in Nasdaq debutThermo FisherIs Thermo Fisher’s New U.S. Bioprocess Design Center Shaping a Deeper Biopharma Strategy for TMO? - simplywall.stThermo FisherIs Thermo Fisher’s New U.S. Bioprocess Design Center Shaping a Deeper Biopharma Strategy for TMO? - simplywall.st
Endpoints News 1. Mai 2026

Boehringer appoints pharma veteran for corporate affairs post; BlueRock CSO heads for the exit

Boehringer appoints pharma veteran for corporate affairs post; BlueRock CSO heads for the exit

Original
Inhalt nicht verfügbar. Bitte die Originalquelle aufrufen.